ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $89,149 | $30 | $1,316 | $5,506 |
| % Growth | 297,063.3% | -97.7% | -76.1% | – |
| Cost of Goods Sold | $20,557 | $0 | $0 | $213 |
| Gross Profit | $68,592 | $30 | $1,316 | $5,293 |
| % Margin | 76.9% | 100% | 100% | 96.1% |
| R&D Expenses | $19,580 | $20,266 | $18,376 | $20,273 |
| G&A Expenses | $0 | $47,284 | $18,456 | $4,687 |
| SG&A Expenses | $0 | $47,284 | $18,456 | $4,687 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $52,095 | $0 | $0 | -$213 |
| Operating Expenses | $71,675 | $67,550 | $36,832 | $24,747 |
| Operating Income | -$3,083 | -$67,520 | -$35,516 | -$19,454 |
| % Margin | -3.5% | -225,066.7% | -2,698.8% | -353.3% |
| Other Income/Exp. Net | $11,369 | $13,155 | $834 | -$789 |
| Pre-Tax Income | $8,286 | -$54,365 | -$34,682 | -$20,243 |
| Tax Expense | $288 | $0 | $0 | $0 |
| Net Income | $7,998 | -$54,365 | -$34,682 | -$20,243 |
| % Margin | 9% | -181,216.7% | -2,635.4% | -367.7% |
| EPS | 0.083 | -0.57 | -0.87 | -0.7 |
| % Growth | 114.5% | 34.5% | -24.3% | – |
| EPS Diluted | 0.078 | -0.57 | -0.87 | -0.7 |
| Weighted Avg Shares Out | 96,937 | 95,215 | 39,956 | 28,872 |
| Weighted Avg Shares Out Dil | 102,391 | 95,215 | 39,956 | 28,872 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $800 |
| Interest Expense | $0 | $0 | $0 | $106 |
| Depreciation & Amortization | $79 | $73 | $319 | $213 |
| EBITDA | -$3,004 | -$67,447 | -$35,197 | -$19,241 |
| % Margin | -3.4% | -224,823.3% | -2,674.5% | -349.5% |